Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 2.009
Filtrer
1.
Braz J Microbiol ; 2024 Aug 26.
Article de Anglais | MEDLINE | ID: mdl-39222222

RÉSUMÉ

OBJECTIVES: The co-circulation of Chikungunya virus (CHIKV) and Dengue virus (DENV) in India poses a challenge for the diagnosing clinician, as they share similar clinical signs and symptoms and geographical distribution. Both arthropod-borne viruses are maintained in the environment by the Aedes mosquito, commonly found in tropical countries including India. Here we aim to investigate the clinical and laboratory aspects of Chikungunya/Dengue suspected cases in Punjab, India during 2021-2022, focusing on the differential diagnosis of Dengue. METHODS: All suspected cases were submitted to serological differential diagnosis approaches to arboviruses like Chikungunya and Dengue. For the detection of Chikungunya Infection, CHIK IgM Capture ELISA was employed. Whereas, for Dengue NS1 antigen ELISA and IgM Capture ELISA assays were employed. RESULTS: A total of 370 cases suspected of arboviral infection were investigated and 38.3% (142/370) were confirmed as Chikungunya. Chikungunya cases were slightly more prevalent in males (54%) and the most frequently affected age group was adults between 16 and 30 years old (45.7%). Polyarthralgia affected 79.5% of patients, 63.3% exhibited headache and 50% presented with retro-orbital pain. 28.9% (107/370) had serological evidence of DENV exposure by detection of specific anti-DENV IgM or NS1 and 9.1% (34/370) cases of co-detection of Chikungunya and Dengue were reported. Urban populations had a higher infection rate of co-detection of Chikungunya and Dengue than rural populations with 83% versus 17%, respectively. CONCLUSIONS: Despite an initial clinical diagnosis of Dengue, most patients with fever and arthralgia were serologically confirmed as Chikungunya cases, with a notable prevalence of CHIKV/DENV co-detection. Strengthening differential diagnosis of circulating arboviruses is crucial for improving patient care and enhancing vector control and environmental management strategies.

2.
Virulence ; 15(1): 2401985, 2024 Dec.
Article de Anglais | MEDLINE | ID: mdl-39263937

RÉSUMÉ

Chikungunya virus (CHIKV) is the causative agent of chikungunya fever (CHIKF), and its primary vectors are the mosquitoes Aedes aegypti and Aedes albopictus. CHIKV was initially endemic to Africa but has spread globally in recent years and affected millions of people. According to a risk assessment by the World Health Organization, CHIKV has the potential seriously impact public health. A growing body of research suggests that mutations in the CHIKV gene that enhance viral fitness in the host are contributing to the expansion of the global CHIKF epidemic. In this article, we review the host-adapted gene mutations in CHIKV under natural evolution and laboratory transmission conditions, which can help improve our understanding of the adaptive evolution of CHIKV and provide a basis for monitoring and early warning of future CHIKV outbreaks.


Sujet(s)
Aedes , Fièvre chikungunya , Virus du chikungunya , Génome viral , Mutation , Virus du chikungunya/génétique , Fièvre chikungunya/virologie , Fièvre chikungunya/transmission , Animaux , Humains , Aedes/virologie , Aedes/génétique , Vecteurs moustiques/virologie , Vecteurs moustiques/génétique , Adaptation à l'hôte/génétique
3.
Can Commun Dis Rep ; 50(9): 294-304, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-39257840

RÉSUMÉ

Background: Climate change is likely to increase the risk of human transmission of arboviruses endemic to Canada, including West Nile virus (WNV), Eastern equine encephalitis virus (EEEV) and California serogroup virus (CSV), calling for enhanced surveillance, including entomological surveillance targeting mosquito vectors. A scoping review was carried out to document the public health contributions of entomological surveillance of arboviruses of importance in Canada. Methods: The Ovid® and EBSCO platforms and the grey literature were searched to identify documents published between 2009 and 2023, in English or French, dealing with entomological surveillance of arboviruses of interest, conducted annually for human health purposes under the aegis of a government authority, with specified public health objectives and actions. Results: The 42 selected publications mainly reported two public health objectives of adult mosquito surveillance: early warning of viral circulation and assessment of the level of risk of human transmission. Recommended actions included clinical preparedness, risk communication, promotion of personal protection measures and vector control. The main objectives of immature mosquito surveillance were to identify sites with high larval densities, in order to reduce/eliminate them and target the application of larvicides. Conclusion: In a context of climate change favouring the spread of arboviruses, this study highlights the potential public health contributions of regular entomological surveillance of endemic arboviruses of importance in Canada. It helps support concrete actions to protect the health of the population from the risks of arboviral transmission.

4.
Euro Surveill ; 29(36)2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-39239729

RÉSUMÉ

While locally-acquired dengue virus (DENV) human infections occur in mainland France since 2010, data to identify the mosquito species involved and to trace the virus are frequently lacking. Supported by a local network gathering public health agencies and research laboratories, we analysed, in late summer 2023, mosquitoes from privately-owned traps within a French urban neighbourhood affected by a dengue cluster. The cluster, in Auvergne-Rhône-Alpes, comprised three cases, including two autochthonous ones. Upon return from a recent visit to the French Caribbean Islands, the third case had consulted healthcare because of dengue-compatible symptoms, but dengue had not been recognised. For the two autochthonous cases, DENV-specific antibodies in serum or a positive quantitative PCR for DENV confirmed DENV infection. The third case had anti-flavivirus IgMs. No DENV genetic sequences were obtained from affected individuals but Aedes albopictus mosquitoes trapped less than 200 m from the autochthonous cases' residence contained DENV. Genetic data from the mosquito-derived DENV linked the cluster to the 2023-2024 dengue outbreak in the French Caribbean Islands. This study highlights the importance of raising mosquito-borne disease awareness among healthcare professionals. It demonstrates Ae. albopictus as a DENV vector in mainland France and the value of private mosquito traps for entomo-virological surveillance.


Sujet(s)
Aedes , Virus de la dengue , Dengue , Animaux , Aedes/virologie , Humains , Dengue/transmission , Dengue/épidémiologie , Dengue/diagnostic , Dengue/virologie , France/épidémiologie , Virus de la dengue/isolement et purification , Virus de la dengue/génétique , Vecteurs moustiques/virologie , Épidémies de maladies , Femelle , Saisons
5.
J Travel Med ; 2024 Sep 10.
Article de Anglais | MEDLINE | ID: mdl-39255380

RÉSUMÉ

BACKGROUND: Over the past 20 years, over 5 million cases of chikungunya, a mosquito-transmitted viral disease, have been reported in over 110 countries. Until recently, preventative strategies for chikungunya were largely ineffective, relying on vector control and individual avoidance of mosquito bites. METHODS: This review outlines the preclinical and clinical efficacy and safety data that led to the approval of VLA1553 (IXCHIQ®), a live-attenuated vaccine against chikungunya disease. It also describes the innovative development pathway of VLA1553, based on an immunological surrogate of protection, and discusses ongoing and future post-licensure studies. RESULTS: In mice and non-human primate models, VLA1553 elicited high titres of neutralizing antibodies, conferred protection against wild-type chikungunya virus challenge and raised no safety concerns. A Phase 1 clinical trial of VLA1553 demonstrated 100% seroconversion among 120 healthy participants, with sustained neutralizing antibody titres after 12 months. These results and determination of a surrogate marker of protection led to advancement of VLA1553 directly into Phase 3 clinical development, as agreed with the US Food and Drug Administration (FDA) and the European Medicines Agency. The pivotal Phase 3 trial met its primary immunogenicity endpoint, achieving seroprotective levels based on immuno-bridging in baseline seronegative participants 28 days post-vaccination. These findings enabled submission of a Biologics License Application to the FDA for accelerated approval of VLA1553 in the US for adults aged ≥18 years. Ongoing and planned studies will confirm the clinical efficacy/effectiveness and safety of VLA1553 in adults and younger individuals, and will generate data in chikungunya endemic countries that have the highest unmet need. CONCLUSION: VLA1553 is the first vaccine approved for the prevention of chikungunya disease in adults, following accelerated development based on a serological surrogate marker of protection. VLA1553 adds to strategies to reduce the spread and burden of chikungunya in endemic populations and travellers.

6.
Front Microbiol ; 15: 1469636, 2024.
Article de Anglais | MEDLINE | ID: mdl-39228382

RÉSUMÉ

[This corrects the article DOI: 10.3389/fmicb.2024.1394661.].

7.
Front Public Health ; 12: 1452758, 2024.
Article de Anglais | MEDLINE | ID: mdl-39220448

RÉSUMÉ

The 2024 Paris Olympics and Paralympics face concerns over dengue virus transmission, despite Paris's lower mosquito activity. Preventive measures include eliminating breeding sites, insecticide spraying, and public awareness. Health systems will monitor and respond to cases. Large gatherings like the Olympics can amplify disease spread, as seen with Zika in Rio 2016. Recent reports confirm dengue presence in Europe, highlighting global risks. While Paris's overall dengue risk is low, even a few cases could impact global health. Collaboration among health authorities, researchers, and event organizers is crucial to ensure participant and public safety during the games.


Sujet(s)
Virus de la dengue , Dengue , Sports , Humains , Dengue/épidémiologie , Dengue/transmission , Dengue/prévention et contrôle , Paris , Animaux , Lutte contre les moustiques
8.
Parasit Vectors ; 17(1): 341, 2024 Aug 13.
Article de Anglais | MEDLINE | ID: mdl-39138532

RÉSUMÉ

BACKGROUND: Rift Valley fever virus (RVFV) is a zoonotic mosquito-borne virus with serious implications for livestock health, human health, and the economy in Africa, and is suspected to be endemic in north-eastern KwaZulu-Natal (KZN), South Africa. The vectors of RVFV in this area are poorly known, although several species, such as Aedes (Neomelaniconion) mcintoshi, Aedes (Neomelaniconion) circumluteolus, Aedes (Aedimorphus) durbanensis, and Culex (Lasioconops) poicilipes may be involved. The aim of the study was to determine the vertebrate blood meal sources of potential RVFV mosquito vectors in north-eastern KZN and to characterize the host-biting network. METHODS: Blood-fed mosquitoes were collected monthly from November 2019 to February 2023 using a backpack aspirator, CO2-baited Centers for Disease Control and Prevention (CDC) miniature light traps and tent traps, in the vicinity of water bodies and livestock farming households. The mosquitoes were morphologically identified. DNA was extracted from individual mosquitoes and used as templates to amplify the vertebrate cytochrome c oxidase I (COI) and cytochrome b (cytb) genes using conventional polymerase chain reaction (PCR). Amplicons were sequenced and queried in GenBank and the Barcode of Life Data systems to identify the vertebrate blood meal sources and confirm mosquito identifications. All mosquitoes were screened for RVFV using real time reverse transcription (RT)-PCR. RESULTS: We identified the mammalian (88.8%) and avian (11.3%) blood meal sources from 409 blood-fed mosquitoes. Aedes circumluteolus (n = 128) made up the largest proportion of collected mosquitoes. Cattle (n = 195) and nyala (n = 61) were the most frequent domestic and wild hosts, respectively. Bipartite network analysis showed that the rural network consisted of more host-biting interactions than the reserve network. All mosquitoes tested negative for RVFV. CONCLUSIONS: Several mosquito species, including Ae. circumluteolus, and vertebrate host species, including cattle and nyala, could play a central role in RVFV transmission. Future research in this region should focus on these species to better understand RVFV amplification.


Sujet(s)
Aedes , Vecteurs moustiques , Fièvre de la Vallée du Rift , Virus de la fièvre de la vallée du Rift , Animaux , République d'Afrique du Sud , Vecteurs moustiques/virologie , Vecteurs moustiques/physiologie , Virus de la fièvre de la vallée du Rift/génétique , Virus de la fièvre de la vallée du Rift/isolement et purification , Virus de la fièvre de la vallée du Rift/physiologie , Fièvre de la Vallée du Rift/transmission , Fièvre de la Vallée du Rift/virologie , Fièvre de la Vallée du Rift/épidémiologie , Aedes/virologie , Aedes/physiologie , Aedes/génétique , Aedes/classification , Humains , Comportement alimentaire , Culex/virologie , Culex/physiologie , Morsures et piqûres d'insectes , Femelle , Culicidae/virologie , Culicidae/physiologie , Culicidae/classification
9.
Ticks Tick Borne Dis ; 15(6): 102388, 2024 Aug 12.
Article de Anglais | MEDLINE | ID: mdl-39137541

RÉSUMÉ

The European Centre for Disease Prevention and Control (ECDC) defines a case of tick-borne encephalitis (TBE) as an infection by the TBE virus (TBEV) with clinical manifestations of central nervous system inflammation (e.g., meningitis, encephalitis). To better understand the TBE surveillance landscape, online searches were conducted to determine if cases of TBE, TBEV infection, acute meningitis or encephalitis, or viral meningitis or encephalitis were subject to statutory reporting in European countries in 2023. In countries with statutory reporting, notification responsibility and available information on surveillance-reported cases were determined. The number of TBE cases reported to ECDC were compared with the number of cases recorded in national surveillance reports. Of 44 countries of the Europe Region of the United Nations, 37 (84 %) mandated statutory reporting of cases of TBE, TBEV infection, or acute/viral meningitis/encephalitis. Twenty-six (87 %) of 30 countries with identified surveillance reports recorded TBE cases in 2020-2023. Of these countries, 17 (65 %) required TBE reporting by clinicians and laboratories, 5 (19 %) by clinicians only, and 4 (15 %) by laboratories only. Twenty-four countries reported on TBE cases to ECDC in 2020; however, surveillance for TBE in Europe is heterogeneous. Standardization of TBE surveillance would enhance the understanding of TBE disease burden in Europe.

11.
Life (Basel) ; 14(8)2024 Aug 15.
Article de Anglais | MEDLINE | ID: mdl-39202755

RÉSUMÉ

Aedes mosquitoes play a pivotal role as vectors of several arboviral diseases, presenting significant public health challenges worldwide. Their invasive success in tropical regions has raised substantial medical concerns. In Guatemala, Aedes mosquitoes are widely distributed and are the primary vectors of the dengue virus. Efforts to control and monitor Aedes populations have evolved over time, incorporating strategies such as spatial repellents, larvicides, genetic modifications, and targeted interventions. Previous research has shown the heterogeneous spatial-temporal distribution of these mosquitoes within each season, influenced by temperature variations and favorable environmental conditions for breeding. This study analyzed hot-spot patterns of spatiotemporal egg density in Santa Elena de la Cruz, Petén, Guatemala, from March to September 2022. The aim was to determine whether these patterns were influenced by non-residential larval habitats with plant cover that are not treated by healthcare entities, as well as the proximity between such habitats. Our findings include the collection and registration of over 16,000 Aedes eggs during the study period. Local analyses revealed hot-spot patterns in egg densities associated with non-residential larval habitats and their proximity. These insights highlight critical focal points where targeted interventions could be implemented more effectively, resulting in cost-efficient mosquito vector control.

12.
Emerg Infect Dis ; 30(9): 1834-1840, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-39173662

RÉSUMÉ

Western equine encephalitis virus (WEEV) is a mosquitoborne virus that reemerged in December 2023 in Argentina and Uruguay, causing a major outbreak. We investigated the outbreak using epidemiologic, entomological, and genomic analyses, focusing on WEEV circulation near the Argentina‒Uruguay border in Rio Grande do Sul state, Brazil. During November 2023‒April 2024, the outbreak in Argentina and Uruguay resulted in 217 human cases, 12 of which were fatal, and 2,548 equine cases. We determined cases on the basis of laboratory and clinical epidemiologic criteria. We characterized 3 fatal equine cases caused by a novel WEEV lineage identified through a nearly complete coding sequence analysis, which we propose as lineage C. Our findings highlight the importance of continued surveillance and equine vaccination to control future WEEV outbreaks in South America.


Sujet(s)
Épidémies de maladies , Virus de l'encéphalite équine de l'Ouest , Épidémiologie moléculaire , Phylogenèse , Animaux , Virus de l'encéphalite équine de l'Ouest/génétique , Humains , Equus caballus , Uruguay/épidémiologie , Amérique du Sud/épidémiologie , Maladies des chevaux/épidémiologie , Maladies des chevaux/virologie , Mâle , Encéphalomyélite équine de l'Ouest/épidémiologie , Encéphalomyélite équine de l'Ouest/virologie , Femelle , Argentine/épidémiologie , Encéphalomyélite équine/épidémiologie , Encéphalomyélite équine/virologie , Encéphalomyélite équine/médecine vétérinaire , Adulte
13.
Expert Rev Vaccines ; 23(1): 773-778, 2024.
Article de Anglais | MEDLINE | ID: mdl-39167081

RÉSUMÉ

INTRODUCTION: Dengue disease represents a large and growing global threat to public health, accounting for a significant burden to health systems of endemic countries. The World Health Organization's (WHO) Strategic Advisory Group of Experts (SAGE) and the European Medicines Agency (EMA) currently recommend the use of TAK-003 dengue vaccine in high dengue burden and transmission settings for countries considering vaccination as part of their integrated management strategy for prevention and control of Dengue. AREAS COVERED: This paper describes the main conclusions of a workshop held by the Arbovirus Committee of the Latin American Society of Pediatric Infectious Diseases (SLIPE) in November 2023, to generate consensus recommendations on the introduction of this new vaccine in the region. Considerations were made regarding the molecular epidemiology of dengue infection in the Americas and the need for more precise phylogenetic classification and correlation with clinical outcome and disease severity. EXPERT OPINION: Introduction of dengue vaccine should be considered as an strategy for health entities in the region, with participation of social sectors, scientific societies, and ministries of health that could be able to create a successful vaccination program.


Sujet(s)
Vaccins contre la dengue , Dengue , Épidémiologie moléculaire , Humains , Vaccins contre la dengue/immunologie , Vaccins contre la dengue/administration et posologie , Dengue/prévention et contrôle , Dengue/épidémiologie , Amérique latine/épidémiologie , Virus de la dengue/immunologie , Virus de la dengue/génétique , Vaccination/méthodes , Phylogenèse , Organisation mondiale de la santé , Programmes de vaccination
14.
Virulence ; 15(1): 2396484, 2024 Dec.
Article de Anglais | MEDLINE | ID: mdl-39193780

RÉSUMÉ

Chikungunya virus (CHIKV) is a mosquito-transmitted, RNA virus that causes an often-severe musculoskeletal illness characterized by fever, joint pain, and a range of debilitating symptoms. The virus has re-emerged as a global health threat in recent decades, spreading from its origin in Africa across Asia and the Americas, leading to widespread outbreaks impacting millions of people. Despite more than 50 years of research into the pathogenesis of CHIKV, there is still no curative treatment available. Current management of CHIKV infections primarily involves providing supportive care to alleviate symptoms and improve the patient's quality of life. Given the ongoing threat of CHIKV, there is an urgent need to better understand its pathogenesis. This understanding is crucial for deciphering the mechanisms underlying the disease and for developing effective strategies for both prevention and management. This review aims to provide a comprehensive overview of CHIKV and its pathogenesis, shedding light on the complex interactions of viral genetics, host factors, immune responses, and vector-related factors. By exploring these intricate connections, the review seeks to contribute to the knowledge base surrounding CHIKV, offering insights that may ultimately lead to more effective prevention and management strategies for this re-emerging global health threat.


Sujet(s)
Fièvre chikungunya , Virus du chikungunya , Humains , Virus du chikungunya/pathogénicité , Virus du chikungunya/génétique , Fièvre chikungunya/virologie , Fièvre chikungunya/épidémiologie , Animaux , Virulence , Vecteurs moustiques/virologie , Interactions hôte-pathogène
15.
Viruses ; 16(8)2024 Jul 24.
Article de Anglais | MEDLINE | ID: mdl-39205160

RÉSUMÉ

Advancing climate change increases the risk of future infectious disease outbreaks, particularly of zoonotic diseases, by affecting the abundance and spread of viral vectors. Concerningly, there are currently no approved drugs for some relevant diseases, such as the arboviral diseases chikungunya, dengue or zika. The development of novel inhibitors takes 10-15 years to reach the market and faces critical challenges in preclinical and clinical trials, with approximately 30% of trials failing due to side effects. As an early response to emerging infectious diseases, CavitOmiX allows for a rapid computational screening of databases containing 3D point-clouds representing binding sites of approved drugs to identify candidates for off-label use. This process, known as drug repurposing, reduces the time and cost of regulatory approval. Here, we present potential approved drug candidates for off-label use, targeting the ADP-ribose binding site of Alphavirus chikungunya non-structural protein 3. Additionally, we demonstrate a novel in silico drug design approach, considering potential side effects at the earliest stages of drug development. We use a genetic algorithm to iteratively refine potential inhibitors for (i) reduced off-target activity and (ii) improved binding to different viral variants or across related viral species, to provide broad-spectrum and safe antivirals for the future.


Sujet(s)
Antiviraux , Infections à arbovirus , Découverte de médicament , Antiviraux/pharmacologie , Antiviraux/composition chimique , Antiviraux/usage thérapeutique , Humains , Virus du chikungunya/effets des médicaments et des substances chimiques , Repositionnement des médicaments , Sites de fixation , Animaux , Protéines virales non structurales/antagonistes et inhibiteurs , Protéines virales non structurales/métabolisme , Arbovirus/effets des médicaments et des substances chimiques
16.
Viruses ; 16(8)2024 Jul 26.
Article de Anglais | MEDLINE | ID: mdl-39205176

RÉSUMÉ

The common house mosquito (Culex pipiens) is a native vector for West Nile virus (WNV). Invasive species like the tiger mosquito (Aedes albopictus) and Asian bush mosquito (Aedes japonicus) are rapidly spreading through Europe, posing a major threat as vectors for dengue, chikungunya (CHIKV), and Japanese encephalitis virus (JEV). These mosquitoes share a similar ecological niche as larvae, but the carry-over effects of aquatic larval interactions to the terrestrial adult stage remain largely unknown and their medical relevance requires further investigation. This study examines the context dependency of larval interactions among Aedes albopictus, Aedes japonicus, and Culex pipiens. The survival, development time, growth, and energetic storage were measured in different European populations within density-response (intraspecific) experiments and replacement (interspecific) experiments at 20 °C and 26 °C. Overall, Ae. japonicus was the weakest competitor, while competition between Ae. albopictus and Cx. pipiens varied with temperature. Adults emerging from this larval competition were infected as follows: Culex pipiens with WNV, Ae. albopictus with CHIKV, and Ae. japonicus with JEV. While no JEV infection was observed, mosquitoes experiencing interspecific interactions during their larval stages exhibited higher infection rates and viral RNA titers for CHIKV and WNV. This increased susceptibility to viral infection after larval competition suggests a higher risk of arbovirus transmission in co-occurring populations.


Sujet(s)
Aedes , Culex , Larve , Vecteurs moustiques , Animaux , Culex/virologie , Culex/croissance et développement , Aedes/virologie , Aedes/croissance et développement , Aedes/physiologie , Larve/virologie , Vecteurs moustiques/virologie , Vecteurs moustiques/croissance et développement , Infections à arbovirus/transmission , Infections à arbovirus/virologie , Arbovirus/physiologie , Virus du Nil occidental/physiologie , Femelle , Virus du chikungunya/physiologie , Virus de l'encéphalite japonaise (espèce)/physiologie
17.
Viruses ; 16(8)2024 Aug 02.
Article de Anglais | MEDLINE | ID: mdl-39205216

RÉSUMÉ

The emergence and re-emergence of arthropod-borne viruses is a public health threat. For routine surveillance in public health laboratories, cost-effective and reproducible methods are essential. In this review, we address the technical considerations of high-throughput sequencing methods (HTS) for arbovirus surveillance in national health laboratories, focusing on pre-sequencing, sequencing, and post-sequencing approaches, underlining the importance of robust wet and dry laboratory workflows for reproducible analysis. We aim to provide insights for researchers and clinicians interested in arbovirus, diagnosis, and surveillance by discussing current advances in sequencing methods and bioinformatics pipelines applied to arboviruses.


Sujet(s)
Infections à arbovirus , Arbovirus , Génomique , Séquençage nucléotidique à haut débit , Santé publique , Arbovirus/génétique , Arbovirus/isolement et purification , Infections à arbovirus/épidémiologie , Infections à arbovirus/diagnostic , Infections à arbovirus/virologie , Humains , Génomique/méthodes , Séquençage nucléotidique à haut débit/méthodes , Animaux , Laboratoires , Biologie informatique/méthodes , Génome viral , Surveillance épidémiologique
18.
Viruses ; 16(8)2024 Aug 09.
Article de Anglais | MEDLINE | ID: mdl-39205250

RÉSUMÉ

Studies on animal virome have mainly concentrated on chordates and medically significant invertebrates, often overlooking sylvatic mosquitoes, constituting a major part of mosquito species diversity. Despite their potential role in arbovirus transmission, the viromes of sylvatic mosquitoes remain largely unexplored. These mosquitoes may also harbor insect-specific viruses (ISVs), affecting arboviral transmission dynamics. The Cerrado biome, known for rapid deforestation and its status as a biodiversity hotspot, offers an ideal setting for investigating mosquito viromes due to potential zoonotic spillover risks from land use changes. This study aimed to characterize the viromes of sylvatic mosquitoes collected from various locations within Minas Gerais state, Brazil. The total RNA was extracted from mosquito pools of Psorophora albipes, Sabethes albiprivus, Sa. chloropterus, Psorophora ferox, and Coquillettidia venezuelensis species, followed by high-throughput sequencing (HTS). Bioinformatic analysis included quality control, contig assembly, and viral detection. Sequencing data analysis revealed 11 near-complete viral genomes (new viruses are indicated with asterisks) across seven viral families and one unassigned genus. These included: Xinmoviridae (Ferox mosquito mononega-like virus* and Albipes mosquito Gordis-like virus*), Phasmaviridae (Sabethes albiprivus phasmavirus*), Lispiviridae (Pedras lispivirus variant MG), Iflaviridae (Sabethes albiprivus iflavivirus*), Virgaviridae (Buriti virga-like virus variant MG and Sabethes albiprivus virgavirus 1*), Flaviviridae (Psorophora ferox flavivirus*), Mesoniviridae (Alphamesonivirus cavallyense variant MG), and the genus Negevirus (Biggie virus variant MG virus and Coquillettidia venezuelensis negevirus*). Moreover, the presence of ISVs and potential novel arboviruses underscores the need for ongoing surveillance and control strategies to mitigate the risk of emerging infectious diseases.


Sujet(s)
Infections à arbovirus , Arbovirus , Culicidae , Vecteurs moustiques , Phylogenèse , Virome , Animaux , Brésil , Arbovirus/génétique , Arbovirus/classification , Arbovirus/isolement et purification , Virome/génétique , Culicidae/virologie , Infections à arbovirus/transmission , Infections à arbovirus/virologie , Vecteurs moustiques/virologie , Génome viral , Séquençage nucléotidique à haut débit , Virus des insectes/génétique , Virus des insectes/classification , Virus des insectes/isolement et purification
19.
Viruses ; 16(8)2024 Aug 14.
Article de Anglais | MEDLINE | ID: mdl-39205271

RÉSUMÉ

Mayaro virus (MAYV) is an arbovirus first isolated in Trinidad and Tobago in 1954. MAYV is the causative agent of Mayaro fever, which is characterised by high fever, maculopapular rash, myalgia and arthralgia. The potential for chronic arthralgia is of particular clinical concern. Currently, MAYV outbreaks are restricted to South and Central America, with some cases reported in Africa as well as several imported cases in Europe. However, in recent years, MAYV has become a growing global concern due to its potential to emerge into urban transmission cycles. Challenges faced with diagnostics, as well as a lack of specific antivirals or licensed vaccines further exacerbate the potential global health threat posed by MAYV. In this review, we discuss this emerging arboviral threat with a particular focus on the current treatment and vaccine development efforts. Overall, MAYV remains a neglected arbovirus due to its limited area of transmission. However, with the potential of its urbanisation and expanding circulation, the threat MAYV poses to global health cannot be overlooked. Further research into the improvement of current diagnostics, as well as the development of efficacious antivirals and vaccines will be crucial to help prevent and manage potential MAYV outbreaks.


Sujet(s)
Infections à alphavirus , Alphavirus , Humains , Alphavirus/isolement et purification , Infections à alphavirus/épidémiologie , Infections à alphavirus/virologie , Infections à alphavirus/transmission , Animaux , Amériques/épidémiologie , Maladies transmissibles émergentes/épidémiologie , Maladies transmissibles émergentes/virologie , Épidémies de maladies , Vaccins antiviraux/immunologie , Antiviraux/usage thérapeutique , Santé mondiale
20.
J Infect Public Health ; 17(9): 102510, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-39088990

RÉSUMÉ

BACKGROUND: Nonspecific acute tropical febrile illnesses (NEATFI) are common in the Latin American tropics. Dengue, Chikungunya, Zika, Mayaro, and Usutu, among others, can coexist in the American tropics. This study aimed to surveil the arboviruses that cause| acute febrile syndrome in patients in the Meta department, Colombia. METHODS: Between June 2021 and February 2023, an epidemiological surveillance study was conducted in the Llanos of the Meta department in Eastern Colombia. RESULTS: One hundred patients in the acute phase with typical prodromal symptoms of NEATFI infection who attended the emergency department of the Villavicencio Departmental Hospital were included. ELISA tests were performed for Dengue, Usutu, Chikungunya, and Mayaro. RT-qPCR was performed to detect the arboviruses Usutu, Dengue, Zika, Mayaro, and Oropouche. The seroprevalence for the Chikungunya, Mayaro, and Usutu viruses was 41 % (28/68), 40 % (27/67), and 62 % (47/75), respectively. Seroconversion for Chikungunya was observed in one patient; two seroconverted to Mayaro and one to Usutu. The NS5 gene fragment of the Usutu virus was detected in nine febrile patients. RT-qPCR of the remaining arboviruses was negative. The clinical symptoms of the nine Usutu-positive patients were very similar to those of Dengue, Chikungunya, Zika, and Mayaro infections. CONCLUSIONS: The pervasive detection of unexpected viruses such as Usutu and Mayaro demonstrated the importance of searching for other viruses different from Dengue. Because Usutu infection and Mayaro fever have clinical features like Dengue, a new algorithm should be proposed to improve the accuracy of acute tropical fevers.


Sujet(s)
Infections à arbovirus , Arbovirus , Surveillance épidémiologique , Humains , Colombie/épidémiologie , Mâle , Femelle , Arbovirus/isolement et purification , Arbovirus/génétique , Infections à arbovirus/épidémiologie , Infections à arbovirus/virologie , Infections à arbovirus/diagnostic , Adulte , Adolescent , Jeune adulte , Adulte d'âge moyen , Études séroépidémiologiques , Fièvre/épidémiologie , Fièvre/virologie , Enfant , Anticorps antiviraux/sang , Enfant d'âge préscolaire , Fièvre chikungunya/épidémiologie , Fièvre chikungunya/diagnostic , Sujet âgé , Test ELISA
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE